Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 36928527

Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
JAMA Oncol
Publication date
2023 May 1
First author
Bryan LJ

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships

    Authors and identifiers

    1. name
      Bryan LJ
      type
      Author
    2. name
      Casulo C
      type
      Author
    3. name
      Allen PB
      type
      Author
    4. name
      Smith SE
      type
      Author
    5. name
      Savas H
      type
      Author
    6. name
      Dillehay GL
      type
      Author
    7. name
      Karmali R
      type
      Author
    8. name
      Pro B
      type
      Author
    9. name
      Kane KL
      type
      Author
    10. name
      Bazzi LA
      type
      Author
    11. name
      Chmiel JS
      type
      Author
    12. name
      Palmer BA
      type
      Author
    Complete bibliographic record and source provenance
    authors
    1. name
      Bryan LJ
      type
      Author
    2. name
      Casulo C
      type
      Author
    3. name
      Allen PB
      type
      Author
    4. name
      Smith SE
      type
      Author
    5. name
      Savas H
      type
      Author
    6. name
      Dillehay GL
      type
      Author
    7. name
      Karmali R
      type
      Author
    8. name
      Pro B
      type
      Author
    9. name
      Kane KL
      type
      Author
    10. name
      Bazzi LA
      type
      Author
    11. name
      Chmiel JS
      type
      Author
    12. name
      Palmer BA
      type
      Author
    bibliography ids
    1. nci-bib-2869e94bc7d606215bcd285b
    book metadata
    content sha256
    70ae38307ad250a6b6643f8243c7a24fb5f80541e0dd69ee7afaac6f500e63c5
    document type
    citation
    dois
    1. 10.1001/jamaoncol.2022.7975
    electronic publication date
    display
    Source null
    precision
    missing
    year
    Source null
    evidence scope
    bibliographic_metadata_only
    id
    pubmed:36928527
    immutable id
    pubmed:36928527@70ae38307ad250a6b6643f8243c7a24fb5f80541e0dd69ee7afaac6f500e63c5
    journal
    abbreviation
    JAMA Oncol
    issn electronic
    2374-2445
    issn print
    2374-2437
    issue
    5
    name
    JAMA oncology
    nlm unique id
    101652861
    pages
    683-691
    volume
    9
    languages
    1. eng
    notices
    absence is not clearance
    true
    has correction metadata
    false
    has expression of concern metadata
    false
    has retraction in link
    false
    pubmed marks article retracted
    false
    pubmed marks retraction notice
    false
    relationships
      outcomes validated
      false
      pmid
      36928527
      provenance
      batch id
      5329a5d0877ee70ecd11
      provider
      NCBI PubMed ESummary
      record sha256
      6f1cfe58a7ed760a2555f2427c01ae5e6cc6a307afa1a13afea78e87ffdaed6e
      response sha256
      bcc4d4935bae07b2d0bf7ef24187cf1ff9d849601f315c9dbe2002bd5de6f631
      retrieved at
      2026-09-09T23:48:15.763286+00:00
      publication date
      display
      2023 May 1
      precision
      day
      year
      2023
      publication types
      1. Multicenter Study
      2. Clinical Trial, Phase II
      3. Journal Article
      4. Research Support, Non-U.S. Gov't
      record status
      PubMed - indexed for MEDLINE
      schema version
      1.0
      source url
      https://pubmed.ncbi.nlm.nih.gov/36928527/
      title
      Pembrolizumab Added to Ifosfamide, Carboplatin, and Etoposide Chemotherapy for Relapsed or Refractory Classic Hodgkin Lymphoma: A Multi-institutional Phase 2 Investigator-Initiated Nonrandomized Clinical Trial.

      Preserved source evidence · Not medical advice